Grafa
MIRA Pharmaceuticals consolidates global rights for pipeline candidates MIRA-55 and SKNY-1
Image for illustrative purposes only. Not a real photo.

MIRA Pharmaceuticals consolidates global rights for pipeline candidates MIRA-55 and SKNY-1

Share

MIRA Pharmaceuticals (NASDAQ:MIRA) announced that it has executed an Amended and Restated Exclusive License Agreement with MIRALOGX.

This strategic move grants MIRA worldwide exclusive rights to its lead candidates, MIRA-55 and SKNY-1, further solidifying the company's control over the development and commercialization of its proprietary therapeutic portfolio.

The agreement consolidates critical operational functions, including global development, commercialization, sublicensing, and intellectual property enforcement.

Notably, the scope of this consolidation extends to the company’s broader pipeline, including the neuropathic pain candidate Ketamir-2.

According to the company, these amendments streamline administrative oversight and operational clarity without materially altering the core economic terms of the original partnership.

By centralizing these rights, MIRA aims to accelerate the advancement of its drug candidates through global regulatory and clinical processes.

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.